Drug Interactions between Cycrin and pexidartinib
This report displays the potential drug interactions for the following 2 drugs:
- Cycrin (medroxyprogesterone)
Interactions between your drugs
Applies to: Cycrin (medroxyprogesterone) and pexidartinib
Pexidartinib may reduce the blood levels and effects of medroxyPROGESTERone. If you are using low-dose oral contraceptives, you may have an increased risk of breakthrough bleeding and unintended pregnancy during combined therapy with pexidartinib. Alternative or additional methods of birth control should be used while taking pexidartinib and for at least one month after stopping pexidartinib. Male patients with female partners who may become pregnant should use effective contraception during and for at least one week after stopping pexidartinib. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
Applies to: pexidartinib
You may experience reduced absorption of pexidartinib in the presence of food. Pexidartinib should be taken on an empty stomach at least 1 hour before or 2 hours after food. This will make it easier for your body to absorb the medication. Also, while taking pexidartinib, you should avoid grapefruits and grapefruit juice. Grapefruit and grapefruit juice can raise the levels of pexidartinib in your body and lead to potentially dangerous adverse effects. Do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.